TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06431204

Intervention type: OTHER
Intervention: Obstetric comorbidity index
Description: Obstetric comorbidity index score
Study: NCT04698291

Intervention type: PROCEDURE
Intervention: Blood Donation
Description: The blood donation will take place at the Gene \& Health clinical assessment centre facilities. A trained member from Gene \& Health program will be responsible for taking the blood samples.

Intervention type: PROCEDURE
Intervention: Blood Donation
Description: The blood donation will take place at the Gene \& Health clinical assessment centre facilities. A trained member from Gene \& Health program will be responsible for taking the blood samples.
Study: NCT05424198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Medial Branch Radiofrequency Ablation
Description: The skin and superficial tissues will be anesthetized at each site with 1-2 mL of lidocaine. Prior to the ablation up to 2 mL of lidocaine may be used at each site to ensure adequate pain control during the ablation. Once in position, a radiofrequency ablation lesion will be made using a 30 second ramp-up time to a maximum temperature of 80 °C, followed by an additional 90 seconds at maximum temperature.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Medial Branch Radiofrequency Ablation
Description: The skin and superficial tissues will be anesthetized at each site with 1-2 mL of lidocaine. Prior to the ablation up to 2 mL of lidocaine may be used at each site to ensure adequate pain control during the ablation. Once in position, a radiofrequency ablation lesion will be made using a 30 second ramp-up time to a maximum temperature of 80 °C, followed by an additional 90 seconds at maximum temperature.
Study: NCT05247489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% cream
Description: Ruxolitinib cream 1.5% applied twice a day (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% cream
Description: Ruxolitinib cream 1.5% applied twice a day (BID).
Study: NCT05726734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin, Metronidazole
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin, Metronidazole
Description: Antibiotics for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study: NCT06320158

Intervention type: OTHER
Intervention: clinical evaluation of sarcopenic obesity
Description: completion of scales and questionnaires, venous blood sampling, muscle ultrasound scan

Intervention type: OTHER
Intervention: clinical evaluation of sarcopenic obesity
Description: completion of scales and questionnaires, venous blood sampling, muscle ultrasound scan
Study: NCT05988281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type I Dental implant placement.
Description: Placement of dental implant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type II Dental implant placement.
Description: Placement of dental implant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type III/IV dental implant placement.
Description: Placement of dental implant.
Study: NCT06569914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humanized care
Description: (1) Humanized environmental care；(2) Humanized medical guidance；(3)Humanized psychological nursing；(4) Humanized and standardized management of IVGTT treatment process
Study: NCT04684862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)
Description: This infusion system is composed of a Medtronic SynchroMed II programmable pump connected to a Intera tapered catheter. Specifically, the Medtronic pump comes with a small connector that ends in a metal flange. During the operation, under sterile conditions, the distal 1 cm of the flange is severed using a scissor. Then, using a Intera connector pin, the end of the Medtronic catheter is connected to the Intera catheter . Two 2-0 silk ties secure the catheters to the pin. The pump and catheter are then inserted into the patient into the abdominal wall or into the chest wall. The catheter is inserted into an artery within the abdomen (usually the gastroduodenal artery but it depends on the exact arterial branching in the individual patient) that feeds the liver.
Study: NCT05836909

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Swisse plus cholesterol capsule
Description: Swisse plus cholesterol capsule per day orally for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05247489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB phototherapy
Description: NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit
Study: NCT06384053

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined
Description: The wIRA device applies hyperthermia by heating the treatment area (with maximum surface temperature set to 43° C), aiming to make cancer cells more sensitive to radiation therapy for non-melanoma skin cancer combined with radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: Radiotherapy is applied.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy (RT)
Description: Radiotherapy is applied.
Study: NCT06211140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: tACS in 4 weeks, once per weekday for 40 minutes each, 20 sessions. The treatment group will receive transcranial alternating current stimulation at a gamma frequency (77.5Hz) with a peak amplitude of 15mA.
Study: NCT05970367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation programme
Description: Intensive rehabilitation using advanced technology, based on the patient's goals.~Including cardiovascular fitness training, goal-oriented training, physiotherapy with and without advanced technology and self-management.
Study: NCT06510075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health intervention
Description: Health care information delivered via a link in a text message that is then opened in a secure browser.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: Health care information delivered via CHW.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Intervention plus Community Health Worker
Description: Health care information delivered via DHI plus CHW
Study: NCT06097897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SVO-ID
Description: Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
Study: NCT06344741

Intervention type: BEHAVIORAL
Intervention: Accepted in latent phase
Description: Participants admitted to the delivery room in the latent phase will be included. Routine procedures will be performed.

Intervention type: BEHAVIORAL
Intervention: Accepted in active phase
Description: Participants admitted to the delivery room in the active phase will be included. Routine procedures will be performed.
Study: NCT05030818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polypill of acetylsalicylic acid, ramipril and atorvastatin
Description: Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin
Description: Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill
Study: NCT05885542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution
Description: Double-blind cannabidiol oral solution 800 mg administered once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind placebo oral solution administered once
Study: NCT05137990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT Exercise Intervention
Description: Exercise trainers will provide encouragement and supervision for exercise prescription adherence and youth will select an age-appropriate music playlist from Spotify to enhance enjoyment throughout each session. Each exercise session consists of a 5-minute warm-up (10% HRmax), followed by a 20-minute HIIT protocol. The 20-minute HIIT protocol consists of seven bouts of 1-min high intensity exercise (90% HRmax) followed by 2-min of active recovery (10% HRmax). Participants will be encouraged to complete each exercise session with at least 24 hours of rest between each session.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching Intervention
Description: This group will perform a home-based program of the same stretches utilized in the exercise group. The stretching protocol consists of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. As flexibility exercises are low-intensity, low-impact and low-volume, minimal caloric expenditure is expected to be incurred. To increase compliance and aid in the standardization of the home-based stretching, participants will be provided a booklet of the flexibility exercises. Participants will be shown how to use the booklet and instructed in the stretching exercises by an exercise trainer prior to the intervention.
Study: NCT06655285

Intervention type: OTHER
Intervention: This was a retrospective study and no patient intervention was performed.
Description: This was a retrospective study and no patient intervention was performed.

Intervention type: OTHER
Intervention: This was a retrospective study and no patient intervention was performed.
Description: This was a retrospective study and no patient intervention was performed.
Study: NCT06211140

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Without the tACS stimulation in this group.
Study: NCT05526508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebound exercise
Description: Exercise training on the rebounder/ mini-trampoline with stability handles attached

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebound exercise
Description: Exercise training on the rebounder/ mini-trampoline with stability handles attached
Study: NCT06042114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surah Inshirah
Description: Patients in the experimental group will be listened to the Surah al-Inshirah after surgery and its effect on pain and anxiety levels will be evaluated.
Study: NCT05708261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MR Intervention
Description: Grounded in Social Cognitive Theory, the intervention delivers five 2-hour sessions with 3 post-session group check-in's to develop skills in partnership communication, HIV disclosure and prevention. The intervention utilizes self-assessments on skills learned and then action plan for these developed and then finalized in the last session.

Intervention type: OTHER
Group type: OTHER
Intervention: Be Well Attention Match
Description: Attention match control arm providing one-way SMS of general health content delivered once per week during the first 5 weeks after enrollment.
Study: NCT06554652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph node tracer navigated selective neck dissection
Description: Selective lateral lymph node dissection (after injection of tracer, lymph nodes in compartment III-IV are dissected; if there is dyed lymph node in compartment IIA, then IIA is dissected).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified neck dissection
Description: Lymph nodes in compartment IIA, IIB, III, IV, VB are dissected.
Study: NCT06512194

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual consists of an integration 1-day, 1-week, and 2-weeks post-psilocybin dosing.
Study: NCT06400056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine
Description: FDA approved
Study: NCT05580146

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zynamite® 15% 150mg
Description: leaves of the mango food plant

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zynamite® 15% 300mg
Description: leaves of the mango food plant

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zynamite® 15% 600mg
Description: leaves of the mango food plant

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sunflower oil matched for appearance
Study: NCT06512194

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual consists of an integration 1-day, 1-week, and 2-weeks post-psilocybin dosing.
Study: NCT06162429

Intervention type: PROCEDURE
Intervention: Flexible Bronchoscopy
Description: Subjects with pleural effusion who underwent medical thoracoscopy using flexible bronchoscopy
Study: NCT05968508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)
Description: A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.
Study: NCT06162429

Intervention type: PROCEDURE
Intervention: Semi-Rigid Pleuroscopy
Description: Subjects with pleural effusion who underwent medical thorascopy using semi-rigid pleuroscopy
Study: NCT05968508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)
Description: A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.
Study: NCT06311851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Infusion of Bevacizumab-loaded hepaspher through transarterial chemoembolization.
Study: NCT05741658

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10mg Tab
Description: Participants will take one Dapagliflozin 10mg tablet once per day for 4 weeks.
Study: NCT05014555

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Three-dose mRNA COVID-19 vaccine per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Three-dose mRNA COVID-19 vaccine per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Three-dose mRNA COVID-19 vaccine per standard of care

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Three-dose mRNA COVID-19 vaccine per standard of care
Study: NCT06348186

Intervention type: OTHER
Group type: OTHER
Intervention: Guidebook
Description: Folder that will be given to the participant to carry out 5 minutes of intervention daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidebook and Myofascial Reorganization® (RMF).
Description: The intervention will be carried out once a week for 30 minutes for 6 weeks. It will include passive, active-assisted moments (with and without load). In addition to a folder that will be given to the participant to carry out 5 minutes of intervention daily.
Study: NCT04952168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
Study: NCT06321471

Intervention type: DEVICE
Group type: OTHER
Intervention: AeviceMD
Description: AeviceMD is a remote patient monitoring system consisting of a wearable stethoscope, silicone patches, a docking station, and a mobile application.
Study: NCT06060418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromtherapy
Description: aromatherapy with essential oil is being used as a non-pharmacological nursing intervention within the health care setting. This approach aims to manage the patient's discomfort and alleviate the symptoms of postoperative nausea and vomiting. One of the most beneficial oils is Lavender Essential Oil (LEO), which is used to treat a variety of digestive issues.
Study: NCT05946798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylcholine
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin aspart
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
Study: NCT05534633

Intervention type: OTHER
Group type: OTHER
Intervention: Choice of STBBI test(s)
Description: Participants may receive a point of care HIV test, and/or point of care HCV test, and/or dry blood spot test, which can test for HIV, HCV, and syphilis, at the participants' choice.
Study: NCT06582251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity functional training
Description: Participants assigned to this group will undergo 8 weeks of high-intensity functional training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional resistance training
Description: Participants assigned to this group will undergo 8 weeks of traditional strength and hypertrophy training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent training
Description: Participants assigned to this group will undergo 8 weeks of traditional strength and hypertrophy training followed by high-intensity interval aerobic training.
Study: NCT05555264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Guided
Description: Clients who select or are assigned the self-guided condition will be able to contact the Online Therapy Unit regarding any technical issues through the secure treatment platform; monitoring staff will respond by secure message to messages received however, no psychological intervention will be provided by monitoring staff as part of the ACCE treatment intervention. If there is a significant clinical issue requiring attention (e.g., a sudden increase in symptoms) monitoring staff will make a telephone call and crisis support will be provided if necessary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-Guided
Description: Therapists will spend \~15 minutes/week communicating with each client who selects the therapist-guided condition, primarily using secure messages. Phone calls will only be made if there is a significant clinical issue requiring attention that the therapist does not feel can be addressed in a message (e.g., a question about the materials that cannot be easily addressed in a text format, a sudden increase in symptoms, increased suicide risk).
Study: NCT06102174

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: Sisunatovir
Study: NCT05209178

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Collection of nasal and oropharyngeal specimen for COVID19 antigen test
Description: Regarding two independent sampling procedures from the anterior part of the nose and the oropharynx, participants are randomized to either perform the sampling by themselves with written instructions or having the procedure performed by trained personnel. The specimen is meant for a rapid antigen test for COVID-19 infection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Collection of nasal and oropharyngeal specimen for COVID19 antigen test
Description: Regarding two independent sampling procedures from the anterior part of the nose and the oropharynx, participants are randomized to either perform the sampling by themselves with written instructions or having the procedure performed by trained personnel. The specimen is meant for a rapid antigen test for COVID-19 infection.
Study: NCT06519825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Inspiratory muscle strength training program will be applied to the FHP-C group for 7 days/6 weeks.